DALLAS, Jan. 15, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring EnteroMedics Inc. (Nasdaq:ETRM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.investorsoup.com/lp/ETRM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
EnteroMedics Inc. (ETRM) is a development-stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders. The Company's neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve using high-frequency, low-energy and electrical impulses. The Company's product under development is the Maestro System, which uses VBLOC therapy to limit the expansion of the stomach, helps control hunger sensations between meals, reduces the frequency and intensity of stomach contractions, and produces a feeling of early and prolonged fullness.
Message Board Search for ETRM: http://www.boardcentral.com/boards/ETRM
In the report, the analyst notes:
"For the three months ended September 30, 2009, the Company reported a net loss of $12.0 million, or $0.40 per share, including non-cash expense of $3.8 million related to the revaluation of warrant liability, research and development expenses of $4.6 million, and general and administrative expenses of $2.7 million. For the nine months ended September 30, 2009, the Company reported a net loss of $29.0 million, or $1.06 per share.
"ETRM recently announced clinical results from two studies of VBLOC(R) vagal blocking therapy, including additional data from its EMPOWER(TM) study in obesity and interim clinical results from its ongoing VBLOC-DM2 ENABLE (DM2) study in diabetes using the next-generation rechargeable (RC) device. For all studies, the Maestro(R) System continues to meet its safety goals, with no therapy-related serious adverse events reported across the various study populations. ...The review further suggested that weight loss effects were evident in both the treatment and control arms because the control arm of the trial, which was intended to be inactive, apparently provided a low-intensity blocking signal that introduced VBLOC Therapy in human subjects."
To read the entire report visit: http://www.investorsoup.com/lp/ETRM
See what investors say about ETRM at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.